All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2020-09-11T10:59:15.000Z

Jorge Sierra outlines the most relevant AML abstracts from EBMT

By Georgia Scurfield, Alice Hyde
Featured
Jorge Sierra
Sep 11, 2020
Share:

Bookmark this article

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to our Executive Steering Committee member, Jorge Sierra, Hospital de la Santa Creu i Sant Pau, Barcelona, ES. This year at EBMT, there were more than 90 abstracts referring to AML, so we asked Prof. Sierra for his highlights.

Jorge Sierra outlines the most relevant AML abstracts from EBMT

In this video, Jorge Sierra breaks down the AML abstracts into several categories, including basic science, conditioning regimens, transplants for specific subgroups, measurable residual disease monitoring pre- and post-transplant, and treatment of relapsed/refractory AML.

More about...
EBMT 2020

Your opinion matters

Do you intend to implement next-generation sequencing for measurable residual disease monitoring in MDS patients?
1 vote - 3 days left ...

Related articles

Add bookmark

EHA 2019 | Why does FLT3 testing need to be performed?

At the 24th Congress of the European Hematology Association (EHA), Jorge Sierra from Hospital de la Santa Creu i Sant Pau, Barcelona, ES, talks about the need to perform FLT3 testing.

Jun 17, 2019
Add bookmark

EHA 2019 | Why does FLT3 testing need to be performed?

At the 24th Congress of the European Hematology Association (EHA), Jorge Sierra from Hospital de la Santa Creu i Sant Pau, Barcelona, ES, talks...

Jun 17, 2019
Add bookmark

Jorge Sierra | EHA 2018 |  Are we moving towards targeting of metabolic pathways and epigenetics in AML?

Jorge Sierra: Hospital Santa Creu I Sant Pau, Barcelona, ES Interview topic: Are we moving towards targeting metabolic pathways and epigenetics...

Jun 21, 2018
Add bookmark

Jorge Sierra | EHA 2018 |  Are we moving towards targeting of metabolic pathways and epigenetics in AML?

Jorge Sierra: Hospital Santa Creu I Sant Pau, Barcelona, ES Interview topic: Are we moving...

Jun 21, 2018

Newsletter

Subscribe to get the best content related to AML delivered to your inbox